New drugs and the management of incontinence Stephen Mark.

Slides:



Advertisements
Similar presentations
Hypertension Medications By: Elizabeth Rangel University of the Incarnate Word.
Advertisements

TO PEE OR NOT TO PEE THAT IS THE QUESTION
Copyright © 2015 Cengage Learning® Chapter 15 Urinary System Drugs.
Darifenacin Hydrobromide
Kathryn L. Burgio, PhD Associate Director for GRECC Research & Patricia S. Goode, MD Associate Director for GRECC Clinical Programs Birmingham/Atlanta.
Objectives Define urinary incontinence
The Overactive Bladder
The Overactive Bladder
Dr Mark Donaldson Consultant Physician in Geriatric Medicine
Overactive Bladder: Diagnosis and Treatment Chase Kenyon Sovell, MD Urology Associates May 30 th, 2007 Pearls of Plumbing Seminar.
GENITAL PROLAPSE DR. IQBAL TURKISTANI Asst. Prof. & Consultant.
OnabotulinumtoxinA (Botox®) for the Treatment of Overactive Bladder
Treatment of Overactive Bladder — What is Best? Presented by (insert name of presenter here)
“URINARY INCONTINENCE IN WOMEN 2013” NICE guidelines implementation in Primary Care Tony Smith Urogynaecologist St Mary’s HospitalAnson Medical CentreManchester.
Benign Prostatic Hypertrophy
Management of Urinary Incontinence
Urinary Incontinence Victoria Cook
Drugs and Urinary Incontinence
Lower Urinary Tract Symptoms (LUTS) in men Kamal Patel GPST2.
2008. Causes of symptoms  Hyperplasia of epithelial and stromal components of prostate  Progressive obstruction of urinary outflow  Increased activity.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 14 Muscarinic Agonists and Antagonists.
ARAVIND EYE CARE SYSTEM Aravind Eye Hospital & Postgraduate Institute of Ophthalmology ARAVIND EYE CARE SYSTEM Aravind Eye Hospital & Postgraduate Institute.
Disability and Incontinence Patient assessment Patient management.
for the Psychiatry Clerkship is proud to present And Now Here Is The Host... Insert Name Here.
Jacob Hummel M.D. Tulane University Anesthesiology.
Continence in the very aged Mark Weatherall University of Otago, Wellington.
LUTS Shawket Alkhayal Consultant Urological Surgeon Benenden Hospital Tunbridge Wells Nuffield Hospital.
MANAGING GENITO-URINARY PROBLEMS THE ROLE OF THE PHARMACIST Dr Rebekah Moles Faculty of Pharmacy
Urology Update Sanofi- Aventis
Check your knowledge in… BHP/LUTS. 5-alpha-reductase inhibitors in the treatment of BPH Induce a significant decrease of libido 2 - Increase maximum.
Basics of outpatient depression management Chris Zamani MD.
Agranulocytosis A acute condition involving a severe and dangerous leukopenia. The absence of Granulocytes.
Erectile Dysfunction Stephen Mark Christchurch. Normal erectile function: Physical and Psychological factors.
GERIATRICS : UI Dr. Meg-angela Christi Amores. URINARY INCONTINENCE  major problem for older adults, afflicting up to 30% of community-dwelling elders.
Anticholinergics in COPD presented by: Soha Ragab Moselhy group 2.
Urinary Incontinence (UI) Management in Family Practice References: Can Fam Physician 2003;49: Can Fam Physician 2003;49: SOGC Clinical.
Over active bladder drug treatment Mark Weatherall University of Otago Wellington.
ECONOMIC EVALUATION OF THE USE OF OXYBUTYNIN, TOLTERODINE AND SOLIFENACIN IN PATIENTS WITH OVERACTIVE BLADDER February 6, 2009.
PELVIC FLOOR Theory update Theory update Workshop Workshop.
Update On OAB Joon Chul Kim The Catholic University of Korea.
PROF. Rosita Aniuliene LITHUANIAN UNIVERSITY OF HEALTH SCIENCES President of Lithuanian Association of Urogynecology.
Dorzolamide A topical Carbonic anhydrase inhibitor. Ampholytic characteristics, hence good corneal penetration (depot effect achieved in cornea). Achieves.
Changing the Landscape of Formulary Modernization: Impact of the Introduction of Generic Products for the Treatment of Overactive Bladder on Reimbursement-Based.
PPS 946 Dr Piascik 1/21/16. At the end of this session, students should be able to:  Describe the types of urinary incontinence  Describe the non-pharmacologic.
TRICYCLICS (TCA). HOW DO THEY WORK? Tricyclic antidepressants are used to treat depression and some other conditions. They often take 2-4 weeks to work.
โดย เภสัชกรณัฐวุฒิ จรีบุญ สมโภช. OAB affects 33 million people in the United States (17% of American adults) more common in women and in older people.
OAB / LUTS Urology Pathway for Primary Care within Frimley Health locality Developed with key local stakeholders including Urologists, Gynaecologists,
Urinary incontinence (UI) Niazy B Hussam Aldin PhD Clinical Pharmacy
Urinary Incontinence A Practical Approach.
Canadian Undergraduate Urology Curriculum (CanUUC): Incontinence
Volume 77, Issue 1, Pages (January 2011)
Biological treatment for OCD
Current Management of OAB
Antimuscarinic drugs for overactive bladder
Pharmacologic therapy of UI
Issues With Bladder Function in MS
Assessment and Management of Urinary Incontinence in the Clinic
Management of Male OAB; Current Status in Japan
Recap last lesson Fill in the blanks..
Bladder Dysfunction Associated With Parkinson’s Disease
Long-Term Management of Overactive Bladder with Antimuscarinic Agents
Volume 54, Issue 4, Pages (October 2008)
Philip Toozs-Hobson, Pallavi Latthe  European Urology Supplements 
Initial Office Evaluation
Intro to Neuromuscular blocking agents
Vidalista 20 Get back a strong Erection with help of Vidalista 20 Buy Now.
Presentation transcript:

New drugs and the management of incontinence Stephen Mark

Drug therapy for incontinence zOAB: Anti cholinergics: different routes, Oxytrol and more selective [ M3], Tolteradine, Solifenacin, Darifenacin. Extended formula’s, Ditropan XL. Botox zSUI: Duloxetine

Normal bladder function Storage: Bladder Outlet Emptying: Bladder Outlet Abnormal bladder function Storage: High P [ OAB ] Treat: Bladder retraining Drugs Surgery

Affects men with BPH Combination medication alpha blocker and anticholinergic being trialled

Bladder retraining Effective Durable Minimum duration 2 months Better results with Continence therapist

Drug treatment: Aims Lower pressure of bladder and increase storage volume Reduce sensitivity bladder Minimal side effects Acceptable costs Drug utilisation is increasing

Drug treatment in OAB zOxybutinin: [ Ditropan ]: Anticholinergic. Direct smooth muscle relaxant [ M1,2,3] and local anaesthetic. Non-selective agent. 70% effective but over 50% stop due to intolerable side effects [ dry mouth, blurred vision, GI symptoms…]. Government funded. zMost commonly used agent

New OAB Medication zEffectiveness zSide effects zCost zRole

Newer drugs for OAB Solifenacin Tolteradine

Ditropan XL zLonger acting Oxybutinin formula zRarely used in NZ zSimilar effectiveness but less side effects

Oxytrol: Oxybutinin patches zAvailable in NZ zSimilar effectiveness but less side effects zDose 2 patches per week zCost: $ 80 - $120 per month

Comparison oral vs transdermal Oxybutinin

Tolterodine [ Detrusitol] zM2 and M3 selective anticholinergic zstudied in adults and children zsimilar effectiveness to Oxybutinin zless side effects zbid dose 2 to 4 mg zCost: $ 80 - $ 120 per month

Comparison Oxybutinin and Tolteradine

Solifenacin [ Vesicare] zM3 selective anticholinergic zstudied in adults zsimilar effectiveness to Oxybutinin zless side effects zonce daily dose 5 or 10 mg zCost: $ 80 - $120 per month

Cost of medication z$ 80 - $120 per month zdependant on pharmacy and location zoccasional company discount

Darifenacin [Enablex] zM3 antagonist znot available in NZ zbid dose

Comparison M3 receptor antagonists

Role of anticholinergics in NZ Oxybutinin fully funded All other drugs equal and similar efficacy All other drugs less side effects Pharmac unlikely to change Dose escalation Oxybutinin to reduce side effects [ except children] Offer alternative if effective and significant side effects Patient will need to pay

Duloxotine for SUI zSerotonin NE uptake inhibitor zanti depressant z10 RCT showing 50% effective in reducing SUI….. Not curative zImproved Qol zSignificant side effects [ 20% withdrawl] zSummary: No role in SUI treatment

The End